Advertisement
Product › Details
fulvestrant
Next higher product group | Antiöstrogen (qm) | |
Status | 1996-01-01 registration start | |
Status | 1998-04-20 development existent | |
Record changed: 2023-07-10 |
Advertisement
More documents for sex hormone or inhibitor
- [1] AstraZeneca plc. (11/15/17). "Press Release: Faslodex Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib"....
- [2] AstraZeneca plc. (11/14/17). "Press Release: Faslodex (fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-positive Advanced Breast Cancer in Combination with Palbociclib"....
- [3] Novartis AG. (8/24/17). "Press Release: Novartis Kisqali (ribociclib) Receives EU Approval as First-line Treatment for HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Combination with any Aromatase Inhibitor". Basel....
- [4] Novartis AG. (3/13/17). "Press Release: Novartis Kisqali (ribociclib, LEE011) Receives FDA Approval as First-line Treatment for HR+/HER2- Metastatic Breast Cancer in Combination with any Aromatase Inhibitor". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top